Consensus ORPEA

Equities

ORP

FR001400NLM4

Market Closed - Euronext Paris Other stock markets 11:39:34 2024-04-19 am EDT			5-day change	1st Jan Change
12.25 ^EUR	-1.95%		+12.10%	-27.51%

Apr. 19	ORPEA : Ready for a refoundation full of thorns
Apr. 17	Emeis: EbitdaR target revised downwards for 2024	CF

Evolution of the average Target Price on ORPEA

Price target over the last 5 years

History of analyst recommendation changes

153fc0049c49ef67.DwUZ6JJzgVmc0QImJcn9e4LYBzQC9WnSgLrTXHE36Ek.SnNNjPUAxw_1uHh2Z46qDcuKV1dlhAue0fuiMDNYvARAM03R4TToac6lTw~e283ee727a13cd10f22fab7b7df5b78d

Analyst Recommendations on ORPEA

ORPEA : Ready for a refoundation full of thorns	Apr. 19
ORPEA : Allowing for the 1,000-to-1 reverse stock split	Mar. 22
ORPEA : Recaps now completed, yet the costly and timely rebuild continues	Feb. 16
ORPEA : Target cut by -11.5%	Feb. 16
Oddo BHF Cuts Orpea PT, Keeps Underperform Opinion	Feb. 16	MT
ORPEA : Oddo BHF maintains 'underperform' rating, reduces target	Feb. 16	CF
ORPEA : A 1,000-to-1 reverse stock split is scheduled to be effective 22 March	Feb. 05
ORPEA : Target cut by -9.6%	Jan. 19
ORPEA : Another unsuccessful Board overhaul following the completion of the second planned recap	Dec. 22
ORPEA : Allowing for the second planned capital increase	Dec. 18
ORPEA : Allowing for the first planned capital increase	Dec. 01
Oddo BHF Maintains Orpea at Underperform, Reduces PT	Nov. 15	MT
ORPEA : Oddo BHF keeps its distance from the stock and reduces its target price	Nov. 15	CF
ORPEA : Gloomier light at the end of the tunnel	Nov. 08
ORPEA : When poor(er) results are no longer news	23-10-16
ORPEA : Integrating the 2022 annual report information	23-07-27
ORPEA : Good-looking organic growth amidst a bleak outlook	23-07-27
ORPEA : Integrating the 2,500x dilution	23-07-25
ORPEA : Allowing for the profit warning	23-07-17
ORPEA : A tougher struggle than had initially been predicted	23-07-17
ORPEA : 250x dilution might not be the worst (?)	23-05-15
ORPEA : Partial integration of the FY22 results	23-05-15
ORPEA : Run for now	23-02-16
ORPEA : In line FY22 revenue; materialising the mammoth dilution	23-02-14
ORPEA : A painful lesson from ESG failure	23-02-03